BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28616676)

  • 1. [Liquid biopsy : A blood sample for early recognition and therapy control in lung cancer patients].
    Hekmat K; Bruns C
    Chirurg; 2017 Jul; 88(7):621. PubMed ID: 28616676
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarker studies abound for early detection of lung cancer.
    Brower V
    J Natl Cancer Inst; 2009 Jan; 101(1):11-3. PubMed ID: 19116384
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor-educated platelet as liquid biopsy in lung cancer patients.
    Liu L; Lin F; Ma X; Chen Z; Yu J
    Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Finding mutations of interest in circulating tumor DNA helps predict immunotherapy response in lung cancer].
    Guibert N; Pradines A; Favre G; Mazières J
    Med Sci (Paris); 2020 May; 36(5):437-439. PubMed ID: 32452359
    [No Abstract]   [Full Text] [Related]  

  • 5. MIRA analysis of RARβ2 gene methylation in DNA circulating in the blood in lung cancer.
    Kapitskaya KY; Azhikina TL; Ponomaryova AA; Cherdyntseva NV; Vlasov VV; Laktionov PP; Rykova EY
    Bull Exp Biol Med; 2014 Aug; 157(4):516-9. PubMed ID: 25110096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients.
    Frattini M; Balestra D; Verderio P; Gallino G; Leo E; Sozzi G; Pierotti MA; Daidone MG
    J Clin Oncol; 2005 May; 23(13):3163-4; author reply 3164-5. PubMed ID: 15860889
    [No Abstract]   [Full Text] [Related]  

  • 7. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of circulating-tumor DNA analysis in non-small cell lung cancer.
    Jiang T; Ren S; Zhou C
    Lung Cancer; 2015 Nov; 90(2):128-34. PubMed ID: 26415994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of K-Ras mutations in non-small cell lung cancer: still an issue for open debate.
    Neri M; Cesario A; Granone P; Dominioni L; Puntoni R; D'Angelillo RM; Russo P
    Lung Cancer; 2006 Sep; 53(3):393-5; author reply 397-8. PubMed ID: 16887233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sMICA as biomarker in detection of non-small-cell lung carcinoma.
    Xing S; Zhu Y; Sun Y
    Br J Biomed Sci; 2018 Jan; 75(1):50-52. PubMed ID: 29182468
    [No Abstract]   [Full Text] [Related]  

  • 13. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.
    Ulivi P; Silvestrini R
    Cell Oncol (Dordr); 2013 Dec; 36(6):439-48. PubMed ID: 24177991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.
    Vallée A; Audigier-Valette C; Herbreteau G; Merrien J; Tessonnier L; Théoleyre S; Denis MG
    Lung Cancer; 2016 Jan; 91():73-4. PubMed ID: 26612314
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumour marker evaluation in patients with lung cancer.
    Seregni E; Botti C; Bogni A; Bombardieri E
    Scand J Clin Lab Invest Suppl; 1995; 221():67-71. PubMed ID: 7652492
    [No Abstract]   [Full Text] [Related]  

  • 18. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
    Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
    Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A blood-based test for epidermal growth factor receptor mutations in lung cancer.
    Bell DW; Haber DA
    Clin Cancer Res; 2006 Jul; 12(13):3875-7. PubMed ID: 16818680
    [No Abstract]   [Full Text] [Related]  

  • 20. Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study.
    Chen K; Zhao H; Yang F; Hui B; Wang T; Wang LT; Shi Y; Wang J
    BMJ Open; 2018 Feb; 8(2):e019012. PubMed ID: 29437753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.